Methods for Treating Pulmonary Hypertension

Abstract

The present invention relates to methods for treating or preventing pulmonary hypertension, reducing mortality in a subject experiencing pulmonary hypertension, or inhibiting ADP-mediated vasoconstriction of pulmonary arteries in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a reversible P2Y 12 receptor antagonist. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments.

1 . A medicament comprising an effective amount of a reversible P2Y 12  receptor antagonist useful for treating or preventing pulmonary hypertension in a subject. 
     
     
         2 . A medicament comprising an effective amount of a reversible P2Y 12  receptor antagonist useful for reducing mortality in a subject experiencing pulmonary hypertension. 
     
     
         3 . A medicament comprising an effective amount of a reversible P2Y 12  receptor antagonist useful for inhibiting ADP-mediated vasoconstriction of pulmonary arteries in a subject. 
     
     
         4 . The medicament of  claim 1 , wherein the reversible P2Y 12  receptor antagonist is a rapid acting antagonist. 
     
     
         5 . The medicament of  claim 1 , wherein the reversible P2Y 12  receptor antagonist is cangrelor. 
     
     
         6 . The medicament of  claim 5 , wherein the medicament comprises 0.1-100 mg/ml cangrelor. 
     
     
         7 . The medicament of  claim 1 , further comprising a pharmaceutically acceptable carrier or diluent. 
     
     
         8 . The medicament of  claim 1 , further comprising an active agent selected from the group consisting of pulmonary vasodilators, digoxin, diuretics, anticoagulants, diuretics, beta blockers, and ACE inhibitors. 
     
     
         9 . (canceled) 
     
     
         10 . The medicament of  claim 1 , wherein the subject:
 (i) has suffered a stroke or a myocardial infarction;   (ii) has diabetes mellitus, hyperlipidemia, congestive heart failure, peripheral arterial disease (PAD), thrombosis in an artery or vein, a family history of coronary artery disease (CAD), or hypertension; or   (iii) has undergone percutaneous transluminal coronary angioplasty (PTCA), coronary intervention (PCI), or artery bypass graft (CABG).   
     
     
         11 - 20 . (canceled) 
     
     
         21 . The medicament of  claim 2 , wherein the reversible P2Y 12  receptor antagonist is a rapid acting antagonist. 
     
     
         22 . The medicament of  claim 2 , wherein the reversible P2Y 12  receptor antagonist is cangrelor. 
     
     
         23 . The medicament of  claim 22 , wherein the medicament comprises 0.1-100 mg/ml cangrelor. 
     
     
         24 . The medicament of  claim 2 , further comprising a pharmaceutically acceptable carrier or diluent. 
     
     
         25 . The medicament of  claim 2 , further comprising an active agent selected from the group consisting of pulmonary vasodilators, digoxin, diuretics, anticoagulants, diuretics, beta blockers, and ACE inhibitors. 
     
     
         26 . The medicament of  claim 2 , wherein the subject:
 (i) has suffered a stroke or a myocardial infarction;   (ii) has diabetes mellitus, hyperlipidemia, congestive heart failure, peripheral arterial disease (PAD), thrombosis in an artery or vein, or a family history of coronary artery disease (CAD); or   (iii) has undergone percutaneous transluminal coronary angioplasty (PTCA), coronary intervention (PCI), or artery bypass graft (CABG).   
     
     
         27 . The medicament of  claim 3 , wherein the reversible P2Y 12  receptor antagonist is a rapid acting antagonist. 
     
     
         28 . The medicament of  claim 3 , wherein the reversible P2Y 12  receptor antagonist is cangrelor. 
     
     
         29 . The medicament of  claim 28 , wherein the medicament comprises 0.1-100 mg/ml cangrelor. 
     
     
         30 . The medicament of  claim 3 , further comprising an active agent selected from the group consisting of pulmonary vasodilators, digoxin, diuretics, anticoagulants, diuretics, beta blockers, and ACE inhibitors. 
     
     
         31 . The medicament of  claim 3 , wherein the subject:
 (i) has suffered a stroke or a myocardial infarction;   (ii) has diabetes mellitus, hyperlipidemia, congestive heart failure, peripheral arterial disease (PAD), thrombosis in an artery or vein, a family history of coronary artery disease (CAD), or hypertension; or   (iii) has undergone percutaneous transluminal coronary angioplasty (PTCA), coronary intervention (PCI), or artery bypass graft (CABG).